South Korea’s Samsung Biologics said on Monday it is acquiring its first US drug production facility from GSK for $280 million to respond to long-term US market demand.
The company’s US unit, Samsung Biologics America, is acquiring a 100 per cent stake in Human Genome Sciences Inc of Rockville, Maryland, the South Korean contract drug manufacturer said in a statement.
Samsung Biologics plans additional investments to expand the site’s capacity, currently a combined 60,000 liters of drug substance capacity, and to upgrade technology, it said.
It added that the acquisition value may change when the deal closes, likely around the end of the first quarter of 2026.
South Korea’s Celltrion is also planning to produce drugs in the United States, where the Trump administration has threatened to levy tariffs on pharmaceuticals.
Under a deal with the United States, tariffs on US imports of South Korean pharmaceuticals will be no greater than 15 per cent, while generic drugs will be tariff-free.
Samsung Biologics shares were down 0.4 per cent on Monday, lagging the wider market’s 2 per cent gain.
Published on December 22, 2025
